换一批
换一批A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
作者：
主题词
投药, 口服(Administration, Oral);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);卡铂(Carboplatin);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);顺铂(Cisplatin);无病生存(Disease-Free Survival);双盲法(Double-Blind Method);临床试验早期终止(Early Termination of Clinical Trials);欧洲(Europe);女(雌)性(Female);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);蛋白激酶抑制剂(Protein Kinase Inhibitors);喹唑啉类(Quinazolines);存活率(Survival Rate);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1016/j.ejca.2011.06.045
PMID
21802939
发布时间
2018-12-01
- 浏览34
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
